Molecular docking analysis of penta-galloyl-glucose with VEGF signaling molecules

Area of Science:

• Biochemistry and Molecular Biology
• Pharmacology
• Oncology

Background:

• The Vascular Endothelial Growth Factor (VEGF) signaling pathway is crucial in cancer progression and angiogenesis.
• Identifying novel compounds that can modulate this pathway is a key strategy in cancer therapy.
• Penta-galloyl-glucose is a natural compound with potential anti-cancer properties.

Purpose of the Study:

• To investigate the molecular interactions between penta-galloyl-glucose and key components of the VEGF signaling pathway.
• To evaluate the binding affinities of penta-galloyl-glucose with specific VEGF signaling molecules using molecular docking.
• To assess the potential of penta-galloyl-glucose as an inhibitor of cancer-related signaling.

Main Methods:

• Molecular docking simulations were performed to analyze the binding of penta-galloyl-glucose.
• The study focused on interactions with VEGF-A, VEGFR-2, and downstream signaling proteins (PKC, RAF, MEK, ERK, AKT).
• Binding affinities were calculated in kcal/mol to quantify the strength of molecular interactions.

Main Results:

• Penta-galloyl-glucose exhibited optimal binding affinities with VEGF-A (-7.9 kcal/mol), VEGFR-2 (-8.3 kcal/mol), and AKT (-10.8 kcal/mol).
• Significant binding was also observed with PKC (-8.6 kcal/mol), MEK (-9 kcal/mol), and ERK (-9 kcal/mol).
• A weaker affinity was noted with RAF (-3.7 kcal/mol).

Conclusions:

• Penta-galloyl-glucose demonstrates favorable molecular interactions with multiple targets in the VEGF signaling pathway.
• The observed binding affinities suggest that penta-galloyl-glucose could potentially inhibit cancer cell proliferation and angiogenesis.
• Further in-vitro and in-vivo studies are warranted to validate these findings and explore therapeutic applications.